Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Sernova (SVA) announced the appointment of Daniel Mahony, Ph.D. to its Board of Directors, effective September 30th, 2022
  • Dr. Mahony is Entrepreneur-in-Residence at Evotec and is also responsible for managing Evotec’s equity investment portfolio
  • Dr. Mahony brings over 25 years of global healthcare investment, management and research experience
  • Sernova is a clinical-stage biotechnology company that is developing products for the treatment of chronic debilitating diseases
  • Sernova Corp. (SVA) is up 0.93 per cent, trading at C$1.08 per share at 3:10 pm ET

Sernova (SVA) has appointed Daniel Mahony, Ph.D., to its Board of Directors, effective September 30th, 2022.

Dr. Mahony is Entrepreneur-in-Residence at Evotec and is also responsible for managing Evotec’s equity investment portfolio.

Dr. Mahony brings over 25 years of global healthcare investment, management and research experience. He has experience in biotechnology, medical technology, and healthcare service sectors. Prior to joining Evotec, he served as the Co-head of Healthcare at Polar Capital. There he launched the firm’s healthcare investment business in 2007 and grew it to over $4 billion of assets under management.

Prior to Polar Capital, he was head of European healthcare research at Morgan Stanley. He was also an analyst at ING Barings Furman Selz in New York, and a postdoctoral research scientist at DNAX Research Institute in California.

Dr. Mahony holds multiple industry leadership positions. He currently chairs the board of the BioIndustry Association (BIA), the industry trade association for UK life sciences. He holds non-executive directorships at the Wellcome Sanger Institute, Trellus Health, Celmatix, Keepabl, and Apian. Dr. Mahony also acts as a mentor for the NHS Clinical Entrepreneur Training Programme.

Dr. Mahony was awarded a first-class, honours degree in biochemistry from Oxford University and received his doctorate degree from Cambridge University. He will replace Dr. Dohrmann as Evotec’s representative on the Sernova board.

Sernova is a clinical-stage biotechnology company that is developing products for the treatment of chronic debilitating diseases.

Sernova Corp. (SVA) is up 0.93 per cent, trading at C$1.08 per share at 3:10 pm ET.


More From The Market Herald

" MCI Onehealth (TSX:DRDR) clinical data insights pipeline gains momentum

MCI Onehealth (DRDR) is evolving its tech and clinical data insights through revenue deals and relationships with businesses in health and life-sciences.

" BriaCell (TSX:BCT) releases positive clinical and quality of life data in advanced metastatic breast cancer study

BriaCell Therapeutics (BCT) presented positive safety/tolerability and efficacy data from its lead product candidate, Bria-IMT.

" Sirona Biochem (TSXV:SBM) begins clinical trial for anti-aging compound TFC-1326

Sirona Biochem Corp. (SBM) has begun the clinical trial for its novel anti-aging compound TFC-1326.
NurExone Biologic Inc - Lior Shaltiel, CEO & Director

" NurExone Biologic (TSXV:NRX) completes securities-for-debt settlement

NurExone Biologic (NRX) has completed its securities-for-debt settlement.